PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025

Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urological solutions, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.

The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access the call through a webcast link or dial-in registration for sell-side analysts. The webcast recording will be available for at least 90 days on the company's investor relations website.

SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics^® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

• Webcast link for interested listeners:
  • https://edge.media-server.com/mmc/p/apg8aowj
    
    
• Dial-in registration for sell-side research analysts:
  • https://register-conf.media-server.com/register/BI6a34da2819a549879a20996d9920dc2f
    
    

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM^® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com

FAQ

When will PROCEPT BioRobotics (PRCT) report Q2 2025 earnings?

PROCEPT BioRobotics will report Q2 2025 earnings on Wednesday, August 6, 2025 after market close.

What time is PROCEPT BioRobotics' Q2 2025 earnings call?

The earnings conference call will begin at 4:30 p.m. Eastern Time on August 6, 2025.

How can investors access PROCEPT BioRobotics' Q2 2025 earnings call?

Investors can access the call through the webcast link on the company's website or through a separate dial-in registration for sell-side analysts.

How long will PROCEPT BioRobotics' Q2 2025 earnings call recording be available?

The webcast recording will be available for at least 90 days after the event on the company's investor relations website.